Please assess the completion status of the following clinical trial:

Trial Title: A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 years of age or older.~* Diagnosis of ulcerative colitis (UC) verified by endoscopy within 60 months prior to consent.~* Severe active disease, as defined by a Modified Truelove \& Witts Severity Index (MTWSI; also known as Lichtiger score) ≥ 11 at consent, with a confirmatory MTWSI ≥ 10 on or after the fifth consecutive day of intravenous (IV)steroids and within 1 day prior to randomization.~* Mayo score ≥ 10 and Mayo mucosal subscore ≥ 2 after a minimum of 3 consecutive days (ie, on or after the fourth consecutive day) of IV steroids.~* Adequate contraception from the day of consent through 3 months after the last dose of study drug.~* Negative serum pregnancy test.~* Negative Clostridium difficile test.~* Signed and dated informed consent and Health Insurance Portability and Accountability Act (HIPAA) if applicable.~Exclusion Criteria:~* UC requiring immediate intervention or toxic megacolon requiring imminent intervention.~* History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis.~* Presence of Ileostomy.~* White blood cell count less than 2.5 x 10\^3/mcL; platelet count less than 150 x 10\^3/mcL; or hemoglobin level less than 8 g/dL.~* Active medically significant infections, particularly those of viral etiology, eg, known cytomegalovirus (CMV) colitis. This includes any incidence of medically significant opportunistic infections within the past 12 months.~* Live vaccination within 6 weeks prior to randomization.~* Significant organ dysfunction, including cardiac, renal, liver, central nervous system (CNS), pulmonary, vascular, gastrointestinal, endocrine, or laboratory abnormality.~* History of myocardial infarction, coronary artery disease, congestive heart failure, or arrythmias within 6 months prior to consent.~* History or treatment of lymphoproliferative disorder (LPD) or malignancy within the past 5 years (excluding nonmelanoma skin cancer or carcinoma in situ of the cervix).~* Seropositivity for infection with human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) surface antigen, or hepatitis C virus (HCV).~* Pregnancy or nursing.~* Treatment with a first dose of infliximab or another anti-tumor necrosis factor (TNF)-α drug within 4 weeks of randomization, or treatment with a subsequent dose of an anti-TNF-α drug within 2 weeks of randomization.~* Treatment with cyclosporine or tacrolimus (FK506) within 2 weeks prior to randomization.~* Treatment with any other investigational drugs or therapies within 60 days prior to randomization, except those mentioned in the two exclusion criteria above.~* Unable or willing to discontinue any UC drug (including, but not limited to 6-mercaptopurine, azathioprine, or methotrexate), except glucocorticoids or 5-ASA, immediately prior to randomization.~* Nontherapeutic levels of chronic antiseizure medications in subjects with a prior history of seizures.~* Any condition that, in the investigator's opinion, makes the subject unsuitable for study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None
- visilizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy